Loading...
Rivastigmine: a placebo controlled trial of twice daily and three times daily regimens in patients with Alzheimer's disease
OBJECTIVE: To evaluate the efficacy and safety of rapidly titrated rivastigmine administered twice (BID) or three times (TID) daily in patients with mild to moderate Alzheimer's disease (AD). METHODS: This was a 26 week international, randomised, double blind, placebo controlled study in which...
Na minha lista:
| Main Authors: | , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
BMJ Group
2007
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2117538/ https://ncbi.nlm.nih.gov/pubmed/17353259 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jnnp.2006.099424 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|